HALDRONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HALDRONE (HALDRONE).
Glucocorticoid receptor agonist; suppresses inflammation and immune responses by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating gene transcription.
| Metabolism | Hepatic; primarily via CYP3A4. |
| Excretion | Renal: 20-30% as unchanged drug; biliary/fecal: 70-80% as metabolites and unchanged drug. |
| Half-life | Terminal elimination half-life: 2.6-3.8 hours. Clinical context: Short half-life requires multiple daily dosing; no significant accumulation with regular dosing. |
| Protein binding | 85-90%, primarily to albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Vd: 1.4-1.6 L/kg. Clinical meaning: Indicates extensive tissue distribution, with high penetration into tissues including brain. |
| Bioavailability | Oral: 60-70% due to first-pass metabolism; IM: 100%. |
| Onset of Action | Oral: 1-2 hours; Intramuscular: 30-60 minutes; Intravenous: within minutes. |
| Duration of Action | Oral: 6-12 hours depending on dose; IM: 12-24 hours; IV: 4-6 hours. Duration is prolonged with higher doses or in hepatic impairment. |
| Molecular Weight | 329.4 |
Oral: Initial dose 50-100 mg twice daily; maintenance 25-50 mg twice daily. Maximum 200 mg/day.
| Dosage form | TABLET |
| Renal impairment | GFR 30-59 mL/min: Reduce dose by 25%. GFR 15-29 mL/min: Reduce dose by 50%. GFR <15 mL/min: Avoid use. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use. |
| Pediatric use | Safety and efficacy not established; use not recommended. |
| Geriatric use | Start at lower end of dosing range; monitor renal function and electrolyte levels. |
| 1st trimester | Avoid during first trimester unless benefit outweighs risk; may cause fetal harm. |
| 2nd trimester | Use with caution; prolonged use may lead to intrauterine growth restriction. |
| 3rd trimester | Use with caution; risk of fetal adrenal suppression. |
Clinical note
Comprehensive clinical and safety monograph for HALDRONE (HALDRONE).
| Placental transfer | Crosses placenta; degree depends on dose and duration. |
| Breastfeeding | Excreted in breast milk; use with caution. Monitor infant for adrenal suppression. |
| Lactation Rating | L3 |
■ FDA Black Box Warning
None.
| Serious Effects |
Systemic fungal infectionsHypersensitivity to any component
| Precautions | Immunosuppression: Increased risk of infections; may mask signs of infection., Hypothalamic-pituitary-adrenal (HPA) axis suppression with prolonged use; taper upon discontinuation., Exacerbation of systemic fungal infections; avoid in active infections without appropriate therapy., May cause gastrointestinal perforation in patients with diverticulitis, fresh intestinal anastomoses, or peptic ulcer disease., May exacerbate diabetes mellitus, hypertension, osteoporosis, and glaucoma., Use caution in patients with congestive heart failure, thromboembolic disorders, and seizure disorders., May cause growth suppression in children; monitor growth in pediatric patients. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit high-sodium foods to reduce fluid retention. Increase calcium and vitamin D intake to counteract bone loss. |
Loading safety data…
| Teratogenic Risk | FDA Pregnancy Category D. Corticosteroids cross the placenta. First trimester: increased risk of cleft palate (odds ratio 3-5). Second/third trimester: fetal adrenal suppression, intrauterine growth restriction, premature rupture of membranes. Chronic exposure may cause neonatal adrenal insufficiency. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of infection. Serial ultrasound for fetal growth and amniotic fluid volume. Assess fetal adrenal function if prolonged therapy near term. |
| Fertility Effects | May impair fertility by disrupting hypothalamic-pituitary-adrenal axis and menstrual cyclicity. Reversible upon dose reduction or discontinuation. No evidence of permanent infertility. |
| Clinical Pearls | HALDRONE (paramethasone acetate) is a potent glucocorticoid with minimal mineralocorticoid activity. Monitor for adrenal suppression during long-term use; taper dose gradually to avoid withdrawal symptoms. May cause hyperglycemia, osteoporosis, and increased infection risk. Use lowest effective dose for shortest duration. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly without consulting your doctor. · Report any signs of infection (fever, sore throat) or unusual bruising/bleeding. · Avoid live vaccines while on this medication. · Carry a medical alert card indicating steroid use in case of emergency. · Do not take with aspirin or NSAIDs unless approved by your doctor due to increased GI bleed risk. |